Full text

Turn on search term navigation

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The ongoing global emergence of arthropod-borne (arbo) viruses has accelerated research into the interactions of these viruses with the immune systems of their vectors. Only limited information exists on how bunyaviruses, such as Rift Valley fever virus (RVFV), are sensed by mosquito immunity or escape detection. RVFV is a zoonotic phlebovirus (Bunyavirales; Phenuiviridae) of veterinary and human public health and economic importance. We have shown that the infection of mosquitoes with RVFV triggers the activation of RNA interference pathways, which moderately restrict viral replication. Here, we aimed to better understand the interactions between RVFV and other vector immune signaling pathways that might influence RVFV replication and transmission. For this, we used the immunocompetent Aedes aegypti Aag2 cell line as a model. We found that bacteria-induced immune responses restricted RVFV replication. However, virus infection alone did not alter the gene expression levels of immune effectors. Instead, it resulted in the marked enhancement of immune responses to subsequent bacterial stimulation. The gene expression levels of several mosquito immune pattern recognition receptors were altered by RVFV infection, which may contribute to this immune priming. Our findings imply that there is a complex interplay between RVFV and mosquito immunity that could be targeted in disease prevention strategies.

Details

Title
Rift Valley Fever Virus Primes Immune Responses in Aedes aegypti Cells
Author
Laureti, Mathilde 1 ; Rui-Xue, Lee 2 ; Bennett, Amelia 3   VIAFID ORCID Logo  ; Wilson, Lucas Aladar 4 ; Sy, Victoria Elena 1 ; Kohl, Alain 2 ; Dietrich, Isabelle 5   VIAFID ORCID Logo 

 The Pirbright Institute, Ash Road, Pirbright GU24 0NF, UK 
 MRC-University of Glasgow Centre for Virus Research, 464 Bearsden Road, Glasgow G61 1QH, UK 
 The Pirbright Institute, Ash Road, Pirbright GU24 0NF, UK; Department of Life Sciences, Faculty of Science, Claverton Down, University of Bath, Bath BA2 7AY, UK 
 The Pirbright Institute, Ash Road, Pirbright GU24 0NF, UK; Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK 
 The Pirbright Institute, Ash Road, Pirbright GU24 0NF, UK; MRC-University of Glasgow Centre for Virus Research, 464 Bearsden Road, Glasgow G61 1QH, UK 
First page
563
Publication year
2023
Publication date
2023
Publisher
MDPI AG
e-ISSN
20760817
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2806605268
Copyright
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.